Fascaplysin (CAS 114719-57-2)
See product citations (5)
QUICK LINKS
Fascaplysin is a chemical compound that functions as a potent inhibitor of cyclin-dependent kinases (CDKs) in various experimental applications. It exerts its mechanism of action by binding to the ATP-binding site of CDKs, thereby preventing the phosphorylation of target proteins involved in cell cycle regulation. This interaction ultimately leads to the inhibition of cell cycle progression and the induction of apoptosis in certain cell types. Fascaplysin may exhibit antiangiogenic properties by targeting vascular endothelial growth factor receptor 2 (VEGFR2), thereby interfering with the formation of new blood vessels. Fascaplysin′s mechanism of action at the molecular level involves disrupting key signaling pathways involved in cell proliferation and angiogenesis, making it useful for investigating these processes in experimental applications.
Fascaplysin (CAS 114719-57-2) References
- A new bioactive sesterterpene and antiplasmodial alkaloids from the marine sponge hyrtios cf. erecta. | Kirsch, G., et al. 2000. J Nat Prod. 63: 825-9. PMID: 10869210
- Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. | Soni, R., et al. 2000. Biochem Biophys Res Commun. 275: 877-84. PMID: 10973815
- DNA binding properties of the marine sponge pigment fascaplysin. | Hörmann, A., et al. 2001. Bioorg Med Chem. 9: 917-21. PMID: 11354674
- Comparison of the Inhibitory Binding Modes Between the Planar Fascaplysin and Its Nonplanar Tetrahydro-β-carboline Analogs in CDK4. | Liang, Y., et al. 2021. Front Chem. 9: 614154. PMID: 33681142
- A pyrone remodeling strategy to access diverse heterocycles: application to the synthesis of fascaplysin natural products. | Palani, V., et al. 2020. Chem Sci. 12: 1528-1534. PMID: 34163915
- Bioactive Compounds with Antiglioma Activity from Marine Species. | Khotimchenko, R., et al. 2021. Biomedicines. 9: PMID: 34440090
- Cytotoxic Marine Alkaloid 3,10-Dibromofascaplysin Induces Apoptosis and Synergizes with Cytarabine Resulting in Leukemia Cell Death. | Spirin, P., et al. 2021. Mar Drugs. 19: PMID: 34564151
- Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer. | Plangger, A., et al. 2022. Invest New Drugs. 40: 215-223. PMID: 34596822
- Fascaplysin derivatives binding to DNA via unique cationic five-ring coplanar backbone showed potent antimicrobial/antibiofilm activity against MRSA in vitro and in vivo. | Wang, X., et al. 2022. Eur J Med Chem. 230: 114099. PMID: 35007859
- Study of Structure-Activity Relationships of the Marine Alkaloid Fascaplysin and Its Derivatives as Potent Anticancer Agents. | Zhidkov, ME., et al. 2022. Mar Drugs. 20: PMID: 35323484
- Fascaplysin Induces Apoptosis and Ferroptosis, and Enhances Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) by Promoting PD-L1 Expression. | Luo, L. and Xu, G. 2022. Int J Mol Sci. 23: PMID: 36430250
- Marine Compounds from the Far Eastern Organisms. | Dyshlovoy, SA., et al. 2023. Mar Drugs. 21: PMID: 36827157
- Design and synthesis of fascaplysin derivatives as inhibitors of FtsZ with potent antibacterial activity and mechanistic study. | Qiu, H., et al. 2023. Eur J Med Chem. 254: 115348. PMID: 37060755
- Marine-Derived Lead Fascaplysin: Pharmacological Activity, Total Synthesis, and Structural Modification. | Wang, C., et al. 2023. Mar Drugs. 21: PMID: 37103365
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Fascaplysin, 1 mg | sc-221607 | 1 mg | $64.00 | |||
Fascaplysin, 5 mg | sc-221607A | 5 mg | $246.00 |